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Abstract
Molecular diagnostics of human cancers may increase accuracy in prognosis, facilitate the selection of the optimal
therapeutic regimen, improve patient outcome, reduce costs of treatment and favour development of personalized
approaches to patient care. Moreover sensitivity and specificity are fundamental characteristics of any diagnostic method.
We developed a highly sensitive microarray for the detection of common KRAS and BRAF oncogenic mutations. In colorectal
cancer, KRAS and BRAF mutations have been shown to identify a cluster of patients that does not respond to anti-EGFR
therapies; the identification of these mutations is therefore clinically extremely important. To verify the technical
characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot
codons 12 and 13 and of the BRAFV600E mutation in colorectal tumor, we selected 75 samples previously characterized by
conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution
Melting analysis and direct sequencing. Among these samples, 60 were collected during surgery and immediately steeped
in RNAlater while the 15 remainders were formalin-fixed and paraffin-embedded (FFPE) tissues. The detection limit of the
proposed method was different for the 7 KRAS mutations tested and for the V600E BRAF mutation. In particular, the
microarray system has been able to detect a minimum of about 0.01% of mutated alleles in a background of wild-type DNA.
A blind validation displayed complete concordance of results. The excellent agreement of the results showed that the new
microarray substrate is highly specific in assigning the correct genotype without any enrichment strategy.
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Introduction
Defining the molecular signature of human cancers could be
central to the development of a personalized approach to patient
care. In fact the identification of appropriate biomarkers might
increase accuracy in prognosis, facilitate the selection of the
optimal therapeutic regimen, improve patient outcome, and
reduce costs of treatment [1]. Thus, stratification of single patients
based on molecular and genetic characteristics is the expected
evolution of the modern clinical oncology.
Recently therapeutic agents targeting specific genetic variants
and well characterized molecular pathways have been developed.
This is the case of the oncogene KRAS which is part of the
signaling pathway of several different molecules. Gain-of-function
missense mutations are often somatically acquired in colorectal
cancer, prevalently at three hot spots represented by codons 12,
13, and 61. Unfortunately, at these levels the number of
substitutions is high, making their detection more complex with
allele specific techniques. Constitutively, activating mutations at
these hot spot sites can determine resistance to EGFR-targeted
therapies which should otherwise significantly improve the survival
rate and the quality of life of patients [2], [3], [4], [5]. The
potential of KRAS codon 12/13 mutations as effective molecular
markers for drug selection has received considerable attention
leading to their use in the routine care of patients with colorectal
cancer [6]. The European health authority (http://www.emea.
europa.eu/pdfs/human/press/pr/ 27923508en.pdf.) as well as the
American Society for Clinical Oncology [7] and the National
Comprehensive Cancer Network (NCCN, http://www.nccn.org/
professionals/physician_gls/PDF/colon.pdf.) require KRAS mu-
tational analysis on colorectal cancer prior to anti-EGFR therapy.
Another promising biomarker of anti-EGFR resistance is
represented by BRAFV600E mutation, that occurs in about 10%
of colorectal cancers. BRAF is the immediate downstream effector
of KRAS in the Ras/Raf/MAPK signaling pathway and
BRAFV600E activating mutation is mutually exclusive for KRAS
mutations [6]. Despite the currently limited data, and lack of
complete consensus, it is likely that BRAF mutations have a role in
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determining the response to anti-EGFR mAb treatment and it is
associated with worse prognosis, independently from treatment
[8], [9]. Furthermore, patients with tumors carrying mutant BRAF
might also benefit from selective BRAF inhibitors such as PLX-
4032 [10].
In the present scenario of screening strategies, the current
methods of analysis (conventional sequencing, pyrosequencing,
etc.) are time-consuming, expensive and lack robustness. Another
emerging issue is connected to the real sensitivity of these methods
that seem to detect minority mutated alleles only when present at
concentrations higher than 10–20%. In previous works [11], [12],
we underlined the importance of sensitivity in the detection of
minority mutated alleles in biological samples and confirmed the
usefulness of COLD-PCR for their enrichment, particularly in
samples with low percentages of tumour cells. On average, 15% of
patients initially classified as negative for KRAS or BRAFV600E
variants were found positive after COLD-PCR [11], [12].
Microarrays represent an inexpensive and accurate tool for
parallel genotyping of multiple markers, suitable for routine
analysis in medical diagnostics [13]. Here, we report on the
development of a highly sensitive microarray for the detection of
KRAS and BRAF mutations. The microarray is developed using a
crystalline silicon slide coated by a thermally grown silicon dioxide
(SiO2) layer and functionalized by adsorption of a copolymer of
dimethylacrylamide (DMA), N-acryloyloxysucinimide (NAS) and
meta-acryloy propyl trimethoxy silane (MAPS), copoly(DMA-
NAS-MAPS), originally developed for glass DNA microarrays
[14]. The backbone of the polymer consists of DMA, a monomer
that adsorbs to the surface by hydrogen bonding; NAS is the
chemically reactive monomer that reacts covalently with bio-
probes, whereas MAPS contribute to film stability by condensing
with surface silanols. The coating procedure is simple and
reproducible, when compared to organo-silanization, a process
that requires highly controlled conditions and suffer from poor
reproducibility. This functional polymer has been widely applied
in the biosensor field for the bio-functionalization of polystyrene
nanobeads [15], silicon microcantilevers [16], polydimethylsilox-
ane [17], and nitrocellulose [18] substrates.
The choice of silicon substrate coated by a layer of SiO2 of
100 nm thickness leads to a strong intensification of fluorescence
on the surface resulting from optical constructive interference
between the incident and reflected lights of the fluorescent
radiation. The condition of constructive interference at the
substrate surface is fulfilled in several types of glass slides coated
with layers of dielectric or metal films [19]. However, the strategy
involved in producing such complex multi-layer structures often
suffers low reproducibility and difficult process control. The
simplest configuration to achieve a fluorescent enhancement close
to that provided by multi-layer slides consists of the silicon planar
reflector coated with a thin film of SiO2 [20], [21] proposed by this
work.
To evaluate technical performances of the newly developed
platform and verify its ability to correct genotyping of KRAS and
BRAFV600E mutations in colorectal tumor samples, we selected 60
tissue samples already classified for these genetic variants by
complete protocols of conventional and COLD-PCR, High
Resolution Melting analysis and direct sequencing. The excellent
outcome of the results will be discussed in order to show the
advantages and the drawbacks of both technologies.
Materials and Methods
Ethics
Tissue samples were collected at Azienda Ospedaliera Uni-
versitaria Careggi in Florence (Italy) from 75 patients undergoing
surgery for CRC in the period 1/6/2009–2/5/2011. All
individuals enrolled in this study provided written informed
consent. The study was approved by the review board of the
University of Florence. Moreover, we used two cell lines provided
by ATCC-LGC Standards Partnership: the CCRF-CEM cell line
as reference for KRAS mutation p.G12D (heterozygous) and the
human melanoma cell line A375 as the source of homozygous
BRAFV600E DNA. The human colorectal carcinoma cell line
SW620 (used as reference for KRAS mutation pG12V, homo-
zygousand the human breast cancer cell line MCF-7 (wild-type for
both KRAS and BRAF genes) were supplied by Banca Biologica e
Cell Factory (IRCCS Azienda Ospedaliera Universitaria San
Martino - IST Istituto Nazionale per la Ricerca sul Cancro).
Sample preparation
Sixty tissue samples were collected during surgery and
immediately steeped in RNAlater (Qiagen Gmbh, Hilden,
Germany) at 4uC for 24 hours and subsequently stored at
280uC until analysis. Tissues were disrupted by Tissue Lyser
with Stainless Steel Beads 5 mm (Qiagen) according to the
manufacturer’s instructions. DNA purification was performed with
QIAcubeTM and QIAamp DNA mini Kit (Qiagen).
The concentration of DNA was determined with Nanodrop
ND-1000 Spectrophotometer (Thermo Scientific, DE, USA).
Figure 1. Assay scheme. Hybridization steps: 1) stabilizer oligonu-
cleotide to open the secondary structure of the PCR fragment; 2) The
‘‘universal reporter mix’’. The mix contains the wild-type and mutant
reporters. Each reporter is prolonged by a tail complementary to the
labeled universal oligonucleotide. Cyanine 3- (Cy3) and Cyanine 5- (Cy5)
labeled universal oligonucleotide anneal to wild-type and mutant
reporters, respectively.
doi:10.1371/journal.pone.0059939.g001
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Moreover, 15 FFPE tissues were also analyzed; DNA from
FFPE tissues was extracted using the FFPE Tissue kit (Qiagen)
following manufacturer’s instruction.
DNA samples were firstly investigated by means of conventional
PCR and COLD-PCR amplification followed by HRM and direct
sequencing. Subsequently they were blindly submitted to the
analysis by the newly developed microarray device to asses its
ability in KRAS and BRAF mutations genotyping.
Positive control samples were represented by DNA of cell lines
harboring mutations in the target genes (See previous section
Ethics). In particular wild-type and mutant samples were assayed
separately as single samples and as mixtures, in order to get known
percentage of mutated allele (from 6% to 0.01%) to be used for the
determination of assay sensitivity for KRAS p.G12D and BRAF
V600E variants.
Moreover, plasmidic DNA containing the wild-type sequences
and alternatively all the considered variants was used to obtain
reconstituted samples to prove assay sensitivity and specificity for
all the other KRAS mutations.
Mutagenesis
Mutant-bearing plasmids were generated through the cloning of
specific mutagenized PCR products harboring the seven mutations
tested in the assay and the corresponding wild-type fragment.
Mutagenized fragments were prepared using a modification of the
method previously reported [22]. Briefly, mutagenesis was
achieved by dividing each amplicon into two fragments. The 59
fragment was then amplified with the original forward primer and
a mutagenizing reverse primer introducing a conservative
transversion. In parallel, the 39 fragment was amplified with the
original reverse primer and a mutagenized forward primer
introducing the same nucleotide variation as above (see Table
S1). This led to the production of two partially overlapping
fragments, which were each gel-eluted in a final volume of 50–
100 mL of distilled water to eliminate non-incorporated primers.
We mixed 2 mL of each eluted solution together; each mixture was
then elongated for 15 cycles in the presence of the PCR reaction
mixture containing all reagents but primers. The product of
elongation reaction, resulting in a full-length centrally mutagen-
ized fragment, was further PCR amplified for 20–30 cycles by
addition of the complete PCR mixture and cloned in the plasmid
vector (TOPO TA Cloning, Invitrogen, LifeTechnologies, Milan,
Italy) according to manufacturer’s protocol. Direct sequencing
confirmed that the desired nucleotide change was introduced into
the mutagenized control.
PCR conditions
Exon 2 of the KRAS gene was amplified with the following
primer set: 59- GCC TGC TGA AAA TGA CTG AA -39
(forward) and 59- AGA ATG GTC CTG CAC CAG TAA-39 (5-
amino-modified, reverse) generating a 167 bp fragment. Primers
used for amplification of BRAF exon 15 (amplicon size 173 bp)
were 59- TGC TTG CTC TGA TAG GAA AAT G-39 (forward)
and 59- CCA CAA AAT GGA TCC AGA CA-39 (5-amino-
modified, reverse).
PCR for both genes was performed in 25 mL reaction
containing 15 ng of DNA, 200 uM of each deoxynucleotide,
10 mM Tris–HCl (pH 8.3), 50 m M KCl, 1.5 mM MgCl2, 1.5 U
of DNA polymerase (AmpliTaq Gold; Applied Biosystems, Foster
City, CA, USA) and 10 pmoles of each primer. Cycling conditions
entailed an initial denaturation at 95uC for 10 min followed by 35
cycles at 95uC for 30 s, 58uC for 30 s and 72uC for 30 s, and a
final elongation at 72uC for 10 min.
Table 1. Sequences of reporters and stabilizer oligonucleotides.
Mutation
(Aminoacid change)
Reporter sequences
(Stabilizer sequences)
Hybridization
temperature (6C)
KRAS
Wild-type 59-*ctgagtccgaacattgag-CTGGTGGCGTA-39
c.35G.C (p.G12A) 59-{ gcagtatatcgcttgaca-CTGCTGGCGTA-39
(59-gcaagagtgccttgacgatacagctattcag-39)
30
c.34G.T (p.G12C) 59-{gcagtatatcgcttgaca- TGGAGCTTGTGG-39
(59-gcaagagtgccttgacgatacagctattcag-39)
41
c.35G.A (p.G12D) 59-{ gcagtatatcgcttgaca- GCTGATGGCGT-39
(59-gcaagagtgccttgacgatacagctattcag-39)
37
c.34G.C (p.G12R) 59-{ gcagtatatcgcttgaca-CTCGTGGCGTA-39
(59-gcaagagtgccttgacgatacagctattcag-39)
30
c.34G.A (p.G12S) 59-{ gcagtatatcgcttgaca-GCTAGTGGCGTA-39
(59-gcaagagtgccttgacgatacagctattcag-39)
36
c.35G.T (p.G12V) 59-{ gcagtatatcgcttgaca-GCTGTTGGCG-39
(59-gcaagagtgccttgacgatacagctattcag-39)
29
c.38G.A (p.G13D) 59-{ gcagtatatcgcttgaca-TGGTGACGTAGG-39
(59-gcaagagtgccttgacgatacagctattcag-39)
36
BRAF
Wild-type 59- *ctgagtccgaacattgag-GCTACAGTGAAATCT-39
V600E 59- { gcagtatatcgcttgaca-GCTACAGAGAAATCT-39
Stab 1 (59-cgatggagtgggtcccatcagtttgaa-39)
Stab 2 (59-gaagacctcacagtaaaaataggtgatttt ggtcta-39)
47
*{Universal reporter formats which hybridize to the universal probes (in small letter); * wild-type sequence-specific tail; { mutant sequence-specific tail.
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference GenBank sequence
(NM_033360.2). The initiation codon is codon 1.
doi:10.1371/journal.pone.0059939.t001
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PCR purification
After the amplification process, each amplicon was purified and
desalted with use of a 96-well plate (Multiscreen-PCR Plates
MANU 030) coupled with the Multiscreen Separation System
(Millipore Corporation, Billerica, MA, USA). PCR products were
eluted in 35 uL of 16printing buffer (150 mM sodium phosphate
pH 8.5).
Reporter and stabilizer design
Reporters were designed in a dot-blot format with the base
variation corresponding to the hotspots located internally (Table 1).
A universal labelling format was used (Figure 1), based on
reporters containing a sequence-specific tail that hybridizes to
universal Cy3 or Cy5 labelled probes (wild-type probe: CTC AAT
GTT CGG ACT CAG-Cy3; mutant probe: TGT CAA GCG
ATA TAC TGC-Cy5) [23].
Table 2. Molecular features of all patients enrolled by HRM-direct sequencing, and microarray.
Sample Number HRM-Sequencing Array Sample Number HRM-Sequencing Array
1 p.G12D p.G12D 31 p.G13C * wt *
2 V600E V600E 32 p.G12V p.G12V
3 p.G12S p.G12S 33 wt wt
4 p.G12V p.G12V 34 p.G12R p.G12R
5 p.G12V p.G12V 35 wt wt
6 p.G12D p.G12D 36 p.G12V p.G12V
7 p.G13D p.G13D 37 p.G12D p.G12D
8 p.G12D p.G12D 38 wt wt
9 p.G12D p.G12D 39 wt wt
10 p.G12D{ p.G12D 40 p.V14I * wt *
11 p.G12C p.G12C 41 p.G12V{ p.G12V
12 p.G13D p.G13D 42 p.G13D{ p.G13D
13 p.G12D{ p.G12D 43 p.G12V{ p.G12V
14 p.G12A p.G12A 44 p.G12V p.G12V
15 p.G13D{ p.G13D 45 p.G12D p.G12D
16 p.G12A{ p.G12A 46 wt wt
17 p.G12S p.G12S 47 V600E V600E
18 p.G13D p.G13D 48 wt wt
19 V600E V600E 49 wt wt
20 p.G12C p.G12C 50 wt wt
21 V600E V600E 51 wt wt
22 V600E V600E 52 p.G12D p.G12D
23 p.G12D p.G12D 53 wt wt
24 p.G12V p.G12V 54 p.G12C p.G12C
25 p.G12A p.G12A 55 V600E V600E
26 p.G12V{ p.G12V 56 wt wt
27 p.G13D p.G13D 57 p.G12V p.G12V
28 V600E V600E 58 p.G12C p.G12C
29 p.G12V p.G12V 59 p.G13D p.G13D
30 p.G12C{ p.G12C 60 p.G12A p.G12A
1 FFPE p.G12A p.G12A 2 FFPE V600E V600E
3 FFPE wt wt 4 FFPE p.G12R p.G12R
5 FFPE wt wt 6 FFPE wt wt
7 FFPE wt wt 8 FFPE p.G13D p.G13D
9 FFPE wt wt 10 FFPE V600E V600E
11 FFPE p.G12C p.G12C 12 FFPE p.G12C p.G12C
13 FFPE V600E V600E 14 FFPE V600E V600E
15 FFPE V600E V600E
*mutation detected only by HRM and sequencing; by microarray analysis, the sample was identified as wild-type since no specific reporter was designed for the
mutation.
{mutation detected by COLD-PCR and sequencing, non detected by conventional PCR.
doi:10.1371/journal.pone.0059939.t002
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Stabilizer (oligonucleotide necessary to open the secondary
structures present in the amplicon) and reporter design was
performed with the help of web-free programs (DNAmfold server:
http://www.bioinfo.rpi.edu/Ezukerm/rna and OligoAnalyzer 3.0
by Integrated DNA Technologies: http://www.idtdna.com) [24].
All reporters were designed using the antisense strand as target
amplicon. All the 7 KRAS mutations were analyzed with the same
stabilizer oligonucleotide reported in Table 1. The codon 600
BRAF mutation required the use of two stabilizers (Stab 1: located
at 59 to the mutation; Stab 2: located at 39 to the mutation,
reported in Table 1).
Silicon slide coating and microarray preparation
Untreated silicon slides 1000A Thermal Oxide (14614 mm2)
were supplied by SVM, Silicon Valley Microelectronics Inc.
(Santa Clara, CA USA). Silicon slides were pre-treated with 0.1 M
sodium hydroxide for 30 min and washed with water and dried.
After pre-treatment, silicon slides were immersed for 30 min in a
copoly(DMA-NAS-MAPS) solution (1% w/v in 0.9 M (NH4)2SO4
water solution). Copoly(DMA-NAS-MAPS) was synthesized and
characterized as described [14].
Slides were finally rinsed with water and dried under vacuum at
80uC.
The PCR products for each gene, amplified from primers with a
59 primary amino-group, necessary to bind the amplicons
covalently to the substrate through a reaction between the amino
groups and the active esters of the polymer coating, were spotted
on the microarray substrates. Three mL of the amino-modified
amplicons were printed in 6 replicates using a piezoelectric spotter,
SciFLEXARRAYER S5 (Scienion Germany), on coated silicon
slides. An amino-modified oligonucleotide labelled with Cy3 was
spotted as a positional reference in four columns in every array.
Spotting conditions was carried out at as described [25]. The
amplicons were coupled to the arrays by incubating in an
uncovered storage box, laid in a sealed chamber, saturated with
sodium chloride (40 g/100 mL H2O) and incubated at room
temperature overnight.
After incubation, all residual reactive groups of the coating
polymer were blocked by dipping the slide in pre-warmed blocking
solution as reported [25].
Figure 2. Microarray image for genotyping the G12R KRAS mutation. (A) microarray scanning of the Cy3 fluorescence signal corresponding
to the wild-type allele. Spots in column 1,2,3,4 represent amino-modified oligonucleotide labelled with Cy3 used as reference spots. (B) scanning of
the Cy5 fluorescence signal corresponding to the mutated allele. (C) microarray spotting scheme. wt: wild-type control samples; het1, het2 and het3:
heterozygous control samples for G12A, G12C, G12R, G12S, G12V, G13D; G12D KRAS mutations; light grey squares represent amino-modified
oligonucleotide labelled with Cy3 used as reference spots. (D) normalized relative fluorescence intensity after hybridization of known control samples
with the reporters complementary to the G12R variation. Bars are the average of the intensity of the 6 replicates of each sample. The error bars are
the standard deviations of the fluorescence intensity of each sample.
doi:10.1371/journal.pone.0059939.g002
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Hybridization
Immediately before hybridization, printed slides were dipped in
0.1 M NaOH for 5 min to denature the double-stranded
immobilized amplicons, subsequently rinsed with water and dried.
Sequences of reporters and stabilizers along with the hybridization
temperatures are detailed in Table 1. In the first step, 0.5 mL of the
stabilizer oligonucleotide were mixed with 49.5 mL of hybridiza-
tion buffer (26 SSC, 0.1% SDS, 0.2 mg/mL BSA) up to 1 mM
final concentration and spread onto the spotted area of the slide.
The slides were incubated at 20uC for 30 min in the Thermomixer
Comfort (Eppendorf) hybridization chamber, and then washed at
room temperature in a 46 SSC buffer to remove the cover slip.
This first wash step was followed by a brief wash (30 s) in a low-salt
buffer (0.26SSC). Then, for the detection of G12S, G12D, G12C,
G12R, G13D KRAS mutations and for the BRAFV600E muta-
tions, the reporter for the wild-type and the mutated sequences
and their corresponding universal oligonucleotides labelled with
Cy3 and Cy5 respectively, were mixed together in equimolar
amounts (final concentration 1 mM) and added to the hybridiza-
tion buffer (26 SSC, 0.1% SDS, 0.2 mg/mL BSA) (see Figure 1
for the assay scheme). In the case of G12A and G12V KRAS
mutations it was necessary to incubate the amplicons in two
consecutive steps. In the first step the amplicons were hybridized
with the reporter complementary to the mutated sequence
together with the corresponding universal oligonucleotide labeled
with Cy5; then, after a brief wash in 46SSC to remove the cover
slip, in the second one the amplicons were hybridized with the
reporter complementary to the wild-type and its corresponding
universal oligonucleotide labeled with Cy3. Both incubations
lasted for 1 hour.
Finally the silicon slides were removed from the hybridization
chamber and soaked briefly in 46SSC buffer to remove the cover
slip, washed twice for 5 min in 26 SSC/0.1% SDS, pre-warmed
at the specific hybridization temperature, then dipped, in
sequence, in a solution 0.26 SSC and 0.16 SSC for 1 min at
room temperature, dried by centrifuging at 780 rpm for 3 min
and scanned.
Image scanning and data analysis
ProScanArray (Perkin Elmer, MA, USA) was used to scan the
hybridized slides. In particular a green laser (lex 543 nm/lem
570 nm) for the Cy3 dye and a red laser (lex 633 nm/lem
670 nm) for the Cy5 dye were applied. The photomultiplier
(PMT) tube gain and the laser power changed between
Figure 3. Microarray image for genotyping the V600E BRAF mutation. (A) Cy3 fluorescence signal corresponding to the wild-type allele.
Spots in column 1,2,3,4 represent amino-modified oligonucleotide labelled with Cy3 used as reference spots. (B) Cy5 fluorescence signal
corresponding to the mutated allele. (C) microarray spotting scheme. wt: wild-type control samples; het1, het2 and het3: heterozygous control
samples; mut: homozygous mutant control sample; light grey squares represent amino-modified oligonucleotide labelled with Cy3 used as reference
spots. (D) normalized relative fluorescence intensity after hybridization of known control samples with the reporters complementary to the V600E
BRAF variation. Bars are the average of the intensity of the 6 replicates of each sample. The error bars are the standard deviations of the fluorescence
intensity of each sample.
doi:10.1371/journal.pone.0059939.g003
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fluorochromes and different experiments. 16-bit TIFF images were
analyzed at 5 mm resolution. Data intensities were extracted with
the scanner software and the data analysis was performed for each
experiment as previously described [25].
Conventional and COLD-PCR amplification followed by
High Resolution Melting (HRM) and direct sequencing
Conventional PCR, COLD-PCR, HRM and sequencing
protocols have been already described [11], [26].
Results
1) Conventional and COLD-PCR amplification HRM and
sequencing results
Initially, all of the 75 samples were screened for the research of
KRAS mutations and BRAFV600E by HRM and sequencing. In a
second phase, all samples (mutated and wild-type) were resubmit-
ted to a complete screening using COLD-PCR amplification
followed by HRM and sequencing as already reported [11].
Globally, 59 out of 75 samples contained alternatively one
mutation either on KRAS hotspots or the BRAFV600E variant,
while 16 were classified as wild type samples and included as
negative controls. It is important to note that in 9/59 mutated
samples, the identification of base substitutions was only made
possible through the use of fast or full COLD-PCR protocols,
probably due to the lower percentages of mutated alleles in the
starting samples. These samples were appositely introduced in the
validation study to test the sensitivity of the proposed platform. For
a detailed description of the distribution of KRAS and BRAF
variants in our samples see Table 2.
2) Optimization of silicon slide analysis
Wild-type control samples and reconstituted heterozygous
control samples (generated by properly mixing plasmidic DNA
containing wild-type and mutated sequences of all 7 KRAS
mutations and of the BRAFV600E variant) were used to test the
assay specificity. Following optimization of temperature and
hybridization time, a correct identification of all genotypes was
achieved. An example is illustrated in Figures 2 and 3 where a
hybridization experiment for the G12R KRAS and the
BRAFV600E mutation is shown, respectively. In the optimized
system, for all the analyzed mutations we could evidence that: i)
fluorescent signals were high, ii) no cross-hybridization was
obtained, even for variants that affect the same or adjacent
Figure 4. Relative fluorescence intensity for detecting the sensitivity of the system. Detection limit of the G13D mutation (A) and of the
V600E BRAF mutation (B). wt: wild-type control samples; het1, het2 and het3: heterozygous control samples; numbers from 1 to 10: serial dilutions,
1 = 6%, 2 = 3%, 3= 1,6%, 4 = 0,8%, 5 = 0.4%, 6 = 0.2%, 7 = 0.1%, 8 = 0.05%, 9 = 0.02%, 10= 0.01% respectively. Bars are the average of the intensity of
the 6 replicates of each sample. The error bars are the standard deviations of the fluorescence intensity of each sample.
doi:10.1371/journal.pone.0059939.g004
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nucleotide positions (Figure 2D) and iii) a good reproducibility
from spot to spot (shown by error bars) was found.
3) Sensitivity of the assay
Sensitivity of the assay in discriminating different proportions of
mutated alleles was evaluated on serial dilutions (6%, 3%, 1,6%,
0,8%, 0.4%, 0.2%, 0.1%, 0.05%, 0.02%, 0.01% mutated/wild-
type) of mutated DNA opportunely mixed with wild-type DNA. In
particular we used CCRF-CEM cell line as reference for KRAS
mutation p.G12D (heterozygous), the human colorectal carcinoma
cell line SW620 (used as reference for KRAS mutation pG12V,
homozygous), and the human melanoma cell lines A375 (used as
the source of homozygous BRAF V600E DNA). The human breast
cancer cell line MCF-7 were used as wild-type for both KRAS and
BRAF genes. For all the other KRAS mutations we used the
mutant-bearing plasmids generated.
The detection limit of the proposed method was different for the
7 KRAS mutations tested and for the V600E BRAF mutation. In
particular, the microarray system has been able to detect a
minimum of about 0.01% of mutated alleles in a background of
wild-type DNA for the G13D mutation, about 0.025% of mutated
allele for the G12R mutation, 0.05% for the G12C mutation,
0.1% for the G12D mutation, 0.2% for the V600E BRAF
mutation, 0.4% for the G12A and the G12S mutations and 0.8%
for the G12V respectively. In Figure 4 two examples of the results
obtained for the G13D KRAS mutation and for the BRAF V600E
mutation are shown.
4) Blind validation
Assay validation was performed in a blinded fashion by
analyzing 75 samples from subjects either positive or wild-type
for KRAS and BRAF mutations, previously characterized by
HRM and direct sequencing. As an example, the microarray
results for the G12C KRAS mutation and for BRAFV600E
mutation for frozen tissues are shown in Figures 5 and 6,
respectively. Moreover in Figure 7 and 8 the microarray results for
the G12R KRAS mutation and for BRAFV600E mutation in FFPE
samples are shown, respectively. The system was highly specific in
assigning the correct genotype to all samples. Blind validation
displayed complete concordance of results (Table 2) with the
Figure 5. Microarray image for the analysis of the G12C KRAS mutation samples. (A) Cy5 fluorescence signal corresponding to the
mutated allele. (B) spotting scheme. wt: wild-type control samples; het1, het2 and het3: heterozygous control samples for G12A, G12C, G12D, G12R,
G12S, G13D, G12V KRAS mutations; numbers from 1 to 60: sixty different solid tumour DNA samples. Grey markers represent the samples positive for
G12C mutation; light grey squares represent an amino-modified oligonucleotide labelled with Cy3 used as reference spots. (C) HRM analysis of
sample number 30 (number 2) compared to melting profiles of control samples (wild-type reference= number 1; mutated reference= number 3) after
amplification by COLD-PCR: the melting behaviour is suggestive for the presence of mutated DNA in the sample. (D) direct sequencing analysis of
sample number 30 submitted to COLD-PCR amplification protocol: the electropherogram confirms the presence of mutated DNA (G12C) in the
sample.
doi:10.1371/journal.pone.0059939.g005
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expected exception of samples N.31 and N.40, carrying the
p.G13C and the p.V14I KRAS variants, which were expressly
introduced to test the specificity of the newly developed probes (see
Table 2).
Discussion
Sensitivity and specificity are fundamental characteristics of any
diagnostic method. Highly sensitive assays, able to detect small
quantities of the substance under investigation, may open new
opportunities in several clinical applications. In particular, the
identification of minority mutated alleles within an excess of wild
type alleles that represents a common problem in the analysis of
cancer DNA, is technically very challenging, and requires the use
of highly sensitive techniques.
Within this context, we aimed at developing innovative
methodologies to improve the detection of very low proportions
of cancer mutations. In this work, rapid detection of KRAS and
BRAF mutations was achieved using a microarray support based
on high-sensitivity silicon slides. Nevertheless, the availability of a
slide with optimized optical properties is just one step toward the
improvement of assay sensitivity. In order to fully take advantage
of its characteristics, the surface must have high binding capacity
and high hybridization yield of the immobilized molecules with
their targets in solution. Hence, it has to be pointed out that the
approach followed for the functionalization of the slides to allow
the immobilization of the amino-modified amplicons is crucial for
the success of the assay. Thus, taking into account these
requirements, we have employed, for amplicon immobilization
on silicon oxide surfaces, a coating procedure that our group has
introduced to functionalize glass, silicon, and other kind of slides
[27]. The combination of surface chemistry and optical slides
properties leads to strong sensitivity increase with an enhancement
of fluorescence signals from four to six times [20] with respect to
glass. The low non-specific background provided by the polymer
coating is an essential requirement to take advantage of
fluorescence intensification as the signal enhancement is not
specific for spot fluorescence. Moreover, the coating procedure is
simple and reproducible and on the surface the polymer forms a
thin film of few nanometers the morphology of which does not
alter the optical properties of Si/SiO2 substrates.
By applying this system, our data indicated the possibility of
identifying at least 0.01% of mutated alleles in a background of
wild-type DNA, based on a dilution curve obtained by serial
dilutions of mutated cancer cell lines and wild-type DNA. This
theoretical sensitivity seems well suited for detecting even a limited
percentage of mutated alleles in a heterogeneous sample, as
obtained from CRC random tissue biopsies. Notably, our previous
experience based on the comparison of conventional PCR versus
COLD-PCR amplification [11] indicates that HRM and direct
sequencing can identify up to 6.2% and 3.1% of mutated allele if
preceded respectively by conventional and COLD-PCR amplifi-
cation [12]. It is relevant to notice how just the use of COLD-PCR
amplification could be determinant for the identification of the
presence of BRAFV600E or KRAS mutations at levels below the
sensitivity of conventional methods [11], [12]. Nevertheless, other
qPCR assays recently introduced on the market (TheraScreenH:
K-RAS Mutation Kit, Elucigene KRAS.BRAF and Exigon)
declare sensitivity levels of 1%, that represent a definite
Figure 6. Microarray image for the analysis of the V600E BRAF mutation samples. (A) Cy3 fluorescence signal corresponding to the wild-
type allele. Spots in column 1,2,3,4 represent amino-modified oligonucleotide labelled with Cy3 used as reference spots. (B) Cy5 fluorescence signal
corresponding to the mutated allele. (C) spotting scheme. wt: wild-type control samples; BRAF het1, het2 and het3: heterozygous control samples;
mut: homozygous mutant control sample; numbers from 1 to 60: sixty different solid tumour samples. Grey markers represent the samples positive
for BRAF mutation; light grey squares represent an amino-modified oligonucleotide labelled with Cy3 used as reference spots.
doi:10.1371/journal.pone.0059939.g006
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improvement compared to conventional PCR and sequencing
methods, but they might be less sensitive that the method
presented in the paper. Our approach could allow for genetic
variants detection down to the level of 0.8–0.01% mutant allele
(depending on each mutation), which is approximately 10–100
fold more sensitive than most of the other available assays.
To test the assay specificity, the system was initially validated on
artificial heterozygous control samples containing wild-type and
mutated sequences of all 7 KRAS mutations and BRAFV600E
mutation. The optimized slide system provided high fluorescence
signals, good reproducibility and allowed correct identification of
all genotypes. The drawbacks of this system are that the
hybridization temperature must be carefully optimized for each
mutation to obtain a specific assignment of the genotype and that
the hybridization temperature is different for each mutation
requiring 7 different microarrays for the 7 KRAS mutations.
Nevertheless the great advantage of the array is that on the same
slide you can spot several samples collected from different patients;
it means that it is possible to screen disease-related mutations of up
to one hundred of individuals on one slide. In this way, hundreds
of genomic samples can be scored in a single experiment, making
it particularly useful for screening large populations for important
markers, such as those implicated in disease susceptibility.
Subsequent blind validation on 75 previously characterized
samples from subjects either positive or wild-type for KRAS and
BRAF mutations indicated 100% agreement for both FFPE and
frozen tissue. The microarray’s performance obtained in the
analysis of FFPE samples is the same shown for the analysis of
DNA extracted from tissue immerse in RNA later where the DNA
integrity is excellent. This condition makes the array useful also in
a clinical setting where the available tumour samples are often
FFPE tissues.
All these data strongly support the application of the newly
developed microarray assay for the scanning of unknown DNA
samples.
KRAS and BRAF mutations are mutually exclusive. In the
current study all 45 KRAS positive samples were wild-type for
BRAFV600E mutation and all 12 BRAF positive samples were wild-
type for KRAS, supporting the mutual exclusiveness of the two
genes in the tumour process.
The development of target therapies has created a clinical need
for a fast and accurate molecular characterisation of tumours.
Understanding which gene is involved in the cancer origin is
mandatory for good clinical practice and allows the physician to
offer their patients better therapeutic choices.
Figure 7. Microarray image for the analysis of the G12R KRAS mutation in FFPE samples. (A) Cy3 fluorescence signal corresponding to the
wild-type allele. Spots in column 1,2,3,4 represent amino-modified oligonucleotide labelled with Cy3 used as reference spots. (B) Cy5 fluorescence
signal corresponding to the mutated allele. (C) spotting scheme. wt: wild-type control samples; het: heterozygous control samples for G12A, G12C,
G12D, G12R, G12S, G12V, G13D, KRAS mutations; numbers from 1 to 15: fifteen different FFPE solid tumour DNA samples. Grey markers represent the
samples positive for G12R mutation; light grey squares represent an amino-modified oligonucleotide labelled with Cy3 used as reference spots. (D)
Relative fluorescence intensity for detecting the sensitivity of the system evaluated for the G12R mutation. wt: wild-type control samples; het:
heterozygous control samples; numbers from 1 to 15: FFPE samples. Bars are the average of the intensity of the 6 replicates of each sample. The error
bars are the standard deviations of the fluorescence intensity of each sample.
doi:10.1371/journal.pone.0059939.g007
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Finally, the method described in this paper represents the first
attempt to generate a platform for the simultaneous and sensitive
detection of a panel of somatic mutations starting from a limited
DNA amount. Obviously, this prototypical approach can be
implemented to reduce cumbersome procedures and introduce
semi-automatic steps.
Moreover, sensitivity is not to be considered a secondary aspect
in view of a possible application to detect mutated alleles in
biofluids, i.e. blood from cancer patients.
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